Financial Performance - Spero reported a net income of $31.5 million for Q4 2025, compared to a net loss of $(20.9) million in Q4 2024, representing a significant turnaround [10]. - Total revenue for Q4 2025 was $41.3 million, up from $15.0 million in Q4 2024, primarily driven by increased collaboration revenue from agreements with GSK and Pfizer [10]. - Total revenue for the year ended December 31, 2025, was $66.8 million, compared to $48.0 million in 2024, reflecting a year-over-year increase of 39.2% [10]. - Spero received a $25 million milestone payment from GSK in Q1 2026 related to the NDA resubmission [10]. - Total liabilities decreased to $9.9 million as of December 31, 2025, from $64.4 million in 2024, indicating improved financial health [15]. Expenses - Research and development expenses decreased to $5.6 million in Q4 2025 from $28.8 million in Q4 2024, reflecting reduced clinical trial activity [10]. - General and administrative expenses for Q4 2025 were $4.3 million, down from $7.1 million in Q4 2024, due to lower legal and personnel-related costs [10]. Cash Position - As of December 31, 2025, Spero had cash and cash equivalents of $40.3 million, sufficient to fund operations into 2028 [10]. Regulatory and Clinical Updates - The NDA for tebipenem HBr was resubmitted to the FDA in December 2025, with a PDUFA date set for June 18, 2026 [5]. - The Phase 3 PIVOT-PO trial for tebipenem HBr demonstrated non-inferiority to intravenous imipenem-cilastatin, with results presented at IDWeek 2025 [5].

Product Development and Approval - As of March 2025, the company has ceased development of the SPR206 program and the SPR720 oral program, focusing resources on the tebipenem HBr program and collaboration with GSK[225]. - The company's business and prospects are substantially dependent on the tebipenem program and the collaboration with GSK, which has the right to terminate the GSK License Agreement under certain conditions[227]. - The company currently has no products approved for sale and has invested a significant portion of its resources in the development of tebipenem HBr for treating bacterial infections causing cUTI[228]. - The ability to realize the value of tebipenem HBr depends on obtaining FDA approval, which may impose requirements that could impact commercialization attractiveness[228]. - Clinical trials are expensive and inherently uncertain, with the potential for unfavorable results leading to additional costs or delays in product development[229]. - The company may face significant delays or abandonment of clinical trials if unable to enroll a sufficient number of patients, impacting the ability to seek marketing approval[242]. - The FDA has mandated the submission of a diversity action plan (DAP) for Phase 3 clinical trials, which may affect planning and timing of future trials[243]. - The FDA's draft guidance on DAPs, which has the force of law, was restored following a court ruling, creating uncertainty around its implementation[244]. - Clinical trials may produce negative or inconclusive results, which could lead to additional trials or studies being required[245]. - The company has ceased development of the SPR720 oral program and shifted focus to the tebipenem HBr program as of November 2025[257]. - The company has received fast track designation for tebipenem HBr for the treatment of cUTI, including pyelonephritis, which may allow for a rolling review process by the FDA[371]. - The FDA's priority review designation aims for a six-month review period for marketing applications, but does not guarantee approval within that timeframe[372]. - The company has negotiated a Special Protocol Assessment (SPA) agreement with the FDA for the pivotal Phase 3 clinical trial of tebipenem HBr, but this does not guarantee approval[374]. - The lengthy and unpredictable nature of the regulatory approval process may significantly impact the company's ability to commercialize its product candidates[368]. - The company must demonstrate the safety and efficacy of its product candidates to obtain regulatory approval, which may require extensive clinical data[366]. - The FDA may require additional clinical trials or impose restrictions on approved products, which could delay commercialization[369]. - The company faces risks related to the interpretation of clinical trial data and the potential for regulatory changes that could affect approval outcomes[370]. Financial Performance and Funding - The company currently has no products approved for sale and cannot guarantee future marketable products[245]. - The company has not generated any revenue from product sales and has incurred losses since its inception in 2013, with a net loss of $68.6 million for the year ended December 31, 2024[297]. - As of December 31, 2025, the company had net operating loss carryforwards of $226.1 million, which may be limited in their utilization due to ownership changes[313]. - The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its product candidates through development and marketing approval[299]. - The company has cash and cash equivalents sufficient to fund operations into 2028, but will need additional funding beyond that point to support ongoing activities[305]. - The company has filed a universal shelf registration statement to raise up to $300 million, which may include common stock and other securities[308]. - The company anticipates that any future capital raises may dilute existing stockholders' ownership interests[309]. Market Competition and Commercialization - The company faces substantial competition from major pharmaceutical and biotechnology companies, which may affect its operating results[267]. - Tebipenem HBr, if approved, may face significant pricing competition from established oral therapies like Levaquin and Cipro[268]. - The company intends to use collaborators for commercialization, which may lower product revenues compared to direct marketing[261]. - There is a risk that the company may not achieve market acceptance for any approved product candidates, affecting revenue generation[255]. - The company may incur significant costs and delays in establishing sales and marketing capabilities necessary for product commercialization[260]. - The company may face challenges in recruiting and retaining effective sales and marketing personnel, impacting its commercialization efforts[264]. - The company anticipates that its product candidate, if approved, will be administered in a hospital inpatient setting, where reimbursement is typically a single bundled payment, potentially affecting adoption due to additional costs[272]. - The commercial success of the company's product candidates will heavily depend on coverage and reimbursement availability from government health programs and third-party payors, which may limit profitability[273]. - Third-party payors are increasingly demanding higher levels of evidence for new technologies, which could impact the company's ability to secure coverage and adequate reimbursement rates[274]. Regulatory and Compliance Risks - The company faces risks related to product liability claims, which could divert resources and limit commercialization efforts[280]. - Compliance with environmental, health, and safety laws is critical, as failure to comply could result in significant fines and adversely affect the company's operations[282]. - The company is subject to evolving data protection laws, such as the California Consumer Privacy Act and the California Privacy Rights Act, which may increase compliance costs and potential liabilities[290]. - The company may incur substantial costs to comply with current or future environmental regulations, which could impair research and development efforts[286]. - Cybersecurity incidents pose a risk to the company's operations, potentially leading to significant disruptions and financial losses[287]. - The company is subject to various risks related to compliance with data protection laws, which could result in significant penalties and affect its financial condition[294]. - The company anticipates significant challenges and costs in ensuring compliance with healthcare laws and regulations, which may lead to civil, criminal, and administrative penalties if violations are found[398]. - Changes in FDA policies and regulations could delay or prevent marketing approvals, adversely affecting the company's business and profitability[393]. Intellectual Property and Collaboration - The company faces risks related to patent protection, as competitors may develop similar technologies if adequate protection is not maintained[344]. - The patent application process is expensive and time-consuming, and the company may not be able to file all necessary applications in a timely manner[344]. - The company may become involved in costly litigation to protect its intellectual property, which could divert management's attention and resources[352]. - The company relies on trade secrets and patents to protect its technology, but breaches of confidentiality agreements could harm its competitive position[359]. - The company has limited experience in obtaining regulatory approvals and relies on third-party organizations for support in this process[364]. - The company relies on third-party collaborators for the development and commercialization of product candidates, which may affect control over future success[315]. - Revenue generation from collaborations depends on the performance of third-party collaborators, including milestone payments and royalties[316]. - Significant competition exists in securing suitable collaborators, with risks including potential abandonment of projects and insufficient resource allocation[317]. - The company may need to alter development plans if collaborations are not established, requiring additional funds for commercialization[319]. - Reliance on third parties for clinical trials and studies may lead to delays in obtaining regulatory approvals if they do not meet contractual obligations[322]. - The company contracts with third parties for manufacturing clinical supplies, which increases risks related to supply availability and cost[328]. - The company’s dependence on third-party manufacturers may adversely affect profit margins and timely commercialization of products[337]. - Failure to comply with licensing agreements could result in the loss of important rights for product development and commercialization[338]. Financial Agreements and Milestones - The company received an upfront payment of $66.0 million from GSK for securing rights to tebipenem pivoxil and tebipenem HBr[340]. - A milestone payment of $30.0 million was achieved in Q3 2023 under the GSK License Agreement[340]. - The company is entitled to receive a total of $95.0 million in development milestone payments, payable in four equal semi-annual installments of $23.8 million each from 2024 to 2025[341]. - Future milestone payments under the GSK License Agreement include $25.0 million for NDA submission with the FDA for tebipenem HBr, expected in February 2026, and up to $101.0 million in commercial milestone payments[341]. - Royalties from GSK on annual net sales of licensed products are set at 1% for sales up to $750.0 million, increasing to high single-digit percentages for sales above that threshold[341]. - The company is responsible for the execution and costs of the follow-up Phase 3 clinical trial of tebipenem HBr, while GSK will handle commercialization activities[342]. - The company must comply with obligations to Meiji and GSK to avoid termination of agreements, which could adversely affect product development[343]. Market Exclusivity and Orphan Drug Designation - The company may seek orphan drug designation for future product candidates, which could provide market exclusivity for drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S.[377]. - Orphan designation offers financial incentives such as grant funding for clinical trials, tax advantages, and a seven-year exclusivity period for the first FDA-approved drug for a specific rare disease[378]. - The FDA granted orphan drug designation for SPR720 in March 2020, but development was ceased in November 2025, highlighting the uncertainty in obtaining and maintaining such designations[379]. - The FDA's interpretation of orphan drug exclusivity was reaffirmed in February 2026, allowing multiple versions of the same orphan drug to be approved for different sub-indications[380]. - If tebipenem HBr is approved for treating cUTI, it may receive five-year new chemical entity exclusivity, blocking generic competition during that period[383]. - The company faces risks in obtaining marketing approvals in international jurisdictions, as FDA approval does not guarantee success in other countries[384]. - The EU's new Pharma Package, expected to be adopted by mid-2026, may reduce regulatory data protection and exclusivity periods for orphan drugs, impacting the pharmaceutical industry[385]. - The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) will oversee approvals post-Brexit, with new regulations taking effect in April 2026[386]. Legislative and Regulatory Environment - The Affordable Care Act (ACA) imposes annual fees on manufacturers for certain branded prescription drugs and requires increased rebates under the Medicaid Drug Rebate Program, potentially negatively impacting future revenues[400]. - Medicare payments for items and services, including drugs, have been reduced by 2% due to the Budget Control Act, which could adversely affect payment for approved product candidates[402]. - The Inflation Reduction Act (IRA) mandates that drug manufacturers pay rebates if their drug prices increase faster than inflation, with negotiations for select drugs starting in 2026[404][405]. - The company faces heightened scrutiny over drug pricing practices, with potential legislative changes aimed at increasing transparency and reducing costs for prescription drugs[403]. - Proposed pilot programs under CMS aim to implement a "reference pricing" regime for drugs, which could impose rebates if prices exceed those in economically comparable countries[410]. - The company is subject to the federal Physician Payments Sunshine Act, requiring annual reporting of payments and transfers of value to physicians, which may affect operational practices[401]. - Future healthcare reforms may impose new regulatory requirements or reduce reimbursement for products, adversely affecting the company's business and financial condition[407]. - The company is monitoring ongoing litigation related to the IRA's Drug Price Negotiation Program, which could have unpredictable outcomes affecting operations[406]. - The company is preparing for potential impacts from executive orders aimed at reducing pharmaceutical prices, which may lead to further regulatory changes and litigation[408][409]. - Individual states are increasingly implementing regulations to control pharmaceutical pricing, including price constraints and marketing cost transparency measures[411]. - The IRA introduced a 1% excise tax on certain stock repurchases by publicly traded companies, which could affect financial conditions[413]. - The OBBBA includes tax provisions that may significantly impact business operations, including changes to the business interest deduction and research and development expenditure rules[413]. - The FDA's workforce is expected to decrease by approximately 3,500 employees due to a reorganization, potentially leading to delays in product approvals[418]. - The FDA's budget for Fiscal Year 2026 is approximately $7 billion, with a slight increase in user fees for drug and device companies[418]. - The federal government shutdown on October 1, 2025, lasted for 43 days, during which the FDA could not accept regulatory submissions requiring fee payments[423]. - Disruptions in government agencies, including the FDA, could hinder timely guidance and approval of product candidates, negatively impacting business[417]. - State Medicaid programs are developing strategies that may impose significant coverage barriers for products approved through accelerated pathways[412]. - Regulatory reforms under the Trump Administration may impact the FDA's operations and oversight activities, potentially affecting business[420].

Core Viewpoint - Spero Therapeutics reported significant financial progress in 2025, highlighted by the resubmission of the New Drug Application (NDA) for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections (cUTI), with a decision from the FDA expected by June 18, 2026 [2][5][6]. Financial Results - For Q4 2025, Spero reported a net income of $31.5 million, a turnaround from a net loss of $20.9 million in Q4 2024, resulting in a diluted net income per share of $0.53 compared to a diluted net loss per share of $(0.38) in the previous year [6][19]. - Total revenue for Q4 2025 was $41.3 million, up from $15.0 million in Q4 2024, primarily driven by increased collaboration revenue from agreements with GSK and Pfizer [6][7]. - For the full year 2025, total revenue reached $66.8 million, compared to $48.0 million in 2024, again largely due to collaboration revenue [7]. Research and Development - Research and development expenses for Q4 2025 were $5.6 million, significantly lower than $28.8 million in Q4 2024, with full-year expenses at $38.5 million compared to $96.8 million in 2024, reflecting decreased clinical trial activity [13]. - General and administrative expenses for Q4 2025 were $4.3 million, down from $7.1 million in Q4 2024, with full-year expenses at $21.2 million compared to $23.7 million in 2024, attributed to reduced legal and personnel costs [13]. Cash Position - As of December 31, 2025, Spero had cash and cash equivalents of $40.3 million, which are estimated to be sufficient to fund operations into 2028 [5][13]. - In Q1 2026, Spero received a $25 million milestone payment from GSK related to the NDA resubmission for tebipenem HBr [13]. Tebipenem HBr Program Update - Tebipenem HBr is being developed as an oral alternative to intravenous carbapenems for treating cUTI, including pyelonephritis, with GSK holding the exclusive license for commercialization in most territories [3][6]. - The NDA resubmission is supported by positive results from the Phase 3 PIVOT-PO trial, which demonstrated non-inferiority to intravenous imipenem-cilastatin [6].

Core Viewpoint - Spero Therapeutics, Inc. will report its financial results for Q4 and the full year of 2025 on March 26, 2026, after market close, and will not host a conference call [1]. Company Overview - Spero Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing novel treatments for rare diseases and conditions with high unmet medical needs [2].

Core Insights - Spero Therapeutics, Inc. is focused on developing tebipenem HBr, an investigational oral carbapenem aimed at treating complicated urinary tract infections (cUTI), including pyelonephritis [1] Group 1: Clinical Development - The Phase 3 trial (PIVOT-PO) for tebipenem HBr has successfully met its primary endpoint and was stopped early due to positive results [1]

Core Insights - Spero Therapeutics announced that its development partner GSK has resubmitted a New Drug Application (NDA) for tebipenem HBr to the FDA, which is intended for treating complicated urinary tract infections (cUTI) [1][2] - The NDA resubmission is accompanied by a $25 million milestone payment to Spero, expected in Q1 2026 [1] Group 1: NDA Resubmission and Trial Results - The NDA resubmission is based on positive results from the Phase 3 PIVOT-PO trial, which was halted early for efficacy in May 2025 [2] - Results from the trial were presented at the IDWeek conference in October 2025 [2] Group 2: Licensing and Development Rights - Spero has granted GSK an exclusive license to commercialize tebipenem HBr globally, except for certain Asian territories where Meiji retains rights [2] Group 3: Company Overview - Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections [4]

Financial Performance - Spero reported a net loss of $7.4 million for Q3 2025, a significant improvement compared to a net loss of $17.1 million in Q3 2024, resulting in a diluted net loss per share of $0.13 versus $0.32[13]. - Total revenue for Q3 2025 was $5.4 million, down from $13.5 million in Q3 2024, primarily due to decreased collaboration revenue with GSK and a decline in grant revenue[13]. - General and administrative expenses for Q3 2025 were $4.2 million, down from $5.2 million in Q3 2024, mainly due to reduced personnel-related costs[13]. - Total operating expenses for Q3 2025 were $13.4 million, compared to $32.1 million in Q3 2024, reflecting a significant reduction in costs[19]. Research and Development - Research and development expenses decreased to $8.6 million in Q3 2025 from $26.9 million in Q3 2024, attributed to reduced clinical expenses related to the PIVOT-PO trial and lower costs for the SPR720 program[13]. - Spero has discontinued the SPR720 program in Q3 2025 after reviewing data from Phase 2a and Phase 1 trials[4]. Clinical Trials - The Phase 3 PIVOT-PO trial for tebipenem HBr demonstrated a 58.5% overall success rate compared to 60.2% for intravenous imipenem-cilastatin, indicating non-inferiority[6]. - The PIVOT-PO trial was stopped early for efficacy in May 2025, highlighting the promising results of tebipenem HBr[6]. - Tebipenem HBr is being developed as an oral treatment for complicated urinary tract infections (cUTI) and could provide an alternative to IV therapies, with a potential FDA filing planned for Q4 2025[2][5]. Cash Position - As of September 30, 2025, Spero had cash and cash equivalents of $48.6 million, which is expected to fund operations into 2028[13].

Clinical Development - Tebipenem HBr completed a Phase 3 trial, meeting its primary endpoint and was stopped early for efficacy, with results presented at IDWeek on October 20, 2025 [201][208]. - The company plans to prioritize finalizing Phase 3 clinical trial activities for tebipenem HBr under the GSK License Agreement, with cash runway sufficient to fund operations into 2028 [203]. - The company ceased development of SPR206 and SPR720, focusing on completing obligations under the GSK License Agreement and other corporate activities [202][212]. Financial Performance - As of September 30, 2025, the company had an accumulated deficit of $482.6 million and cash and cash equivalents of $48.6 million, expecting to incur significant expenses and operating losses for at least the next year [203]. - Total revenues for the three months ended September 30, 2025, were $5,442,000, a decrease of $8,027,000 (approximately 59.6%) compared to $13,469,000 in 2024 [232]. - Grant revenue decreased to $2,394,000 in Q3 2025 from $5,650,000 in Q3 2024, a decline of $3,256,000 (approximately 57.5%) primarily due to a reduction in BARDA contract revenue [232]. - Collaboration revenue from GSK fell to $3,048,000 in Q3 2025 from $7,754,000 in Q3 2024, a decrease of $4,706,000 (approximately 60.6%) [233]. - For the nine months ended September 30, 2025, total revenues were $25,505,000, a decrease of $7,428,000 (approximately 22.5%) from $32,933,000 in 2024 [246]. - Collaboration revenue for the nine months ended September 30, 2025, increased to $19,961,000 from $18,040,000 in 2024, an increase of $1,921,000 (approximately 10.7%) driven by GSK [248]. Expenses and Losses - Total operating expenses for Q3 2025 were $13,358,000, down $18,704,000 (approximately 58.3%) from $32,062,000 in Q3 2024 [232]. - Research and development expenses decreased to $8,597,000 in Q3 2025 from $26,864,000 in Q3 2024, a reduction of $18,267,000 (approximately 68.1%) [236]. - The net loss for Q3 2025 was $7,382,000, an improvement of $10,055,000 (approximately 57.6%) compared to a net loss of $17,437,000 in Q3 2024 [232]. - Direct research and development expenses for the nine months ended September 30, 2025, were $32,875,000, down $35,046,000 (approximately 51.6%) from $67,921,000 in 2024 [249]. - Personnel-related costs for the nine months ended September 30, 2025, were $9.8 million, a slight increase of $0.1 million from $9.7 million in 2024, primarily due to retention bonuses and executive severance expenses [253]. - Total general and administrative expenses for the nine months ended September 30, 2025, were $16.9 million, an increase of $0.2 million from $16.6 million in 2024 [253]. Impairment and Other Charges - An impairment charge of $0.6 million was recorded in Q3 2025 related to the right-of-use asset due to a real estate lease evaluation [224]. - The company recognized $1.1 million in expenses related to a strategic restructuring initiative implemented in October 2024, with no further charges expected [225]. - Impairment charges of $587,000 were recognized in Q3 2025, compared to no charges in Q3 2024 [244]. - Impairment charges related to the right of use asset were $0.6 million for the nine months ended September 30, 2025, compared to no charges in the same period of 2024 [257]. Cash Flow and Funding - Cash and cash equivalents as of September 30, 2025, were $48.6 million, providing a runway to fund operating expenses for at least 12 months [259]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $4.3 million, primarily due to a net loss of $22.9 million [262]. - The company did not undertake any investing or financing activities during the nine months ended September 30, 2025 [266][267]. - The company plans to mitigate funding risks through raising additional capital, potential collaborations, and reducing cash expenditures [269]. Revenue Generation and Future Outlook - The company has not generated any revenue from product sales to date, with future revenue dependent on successful regulatory approval of product candidates [214]. - The company anticipates a portion of future revenue will derive from government awards and collaborations with Pfizer and GSK [215][216]. - The company has not yet commercialized any product candidates and may not generate revenue from sales in the near future [259]. Currency Exposure - The company is exposed to foreign currency exchange rate fluctuations, primarily the Euro, British Pound, and Australian Dollar against the U.S. dollar [277].

Core Insights - Spero Therapeutics reported financial results for Q3 2025, highlighting a net loss of $7.4 million, a significant reduction from a net loss of $17.1 million in Q3 2024, indicating improved financial performance [8] - The company is advancing its investigational oral antibiotic, tebipenem HBr, with plans for FDA submission in Q4 2025, potentially offering a new treatment option for complicated urinary tract infections [2][6] Financial Performance - Total revenue for Q3 2025 was $5.4 million, down from $13.5 million in Q3 2024, primarily due to decreased collaboration revenue with GSK and a decline in grant revenue [8] - Research and development expenses decreased to $8.6 million in Q3 2025 from $26.9 million in the same period in 2024, attributed to reduced clinical expenses related to the PIVOT-PO trial and lower costs associated with the SPR720 program [8] - General and administrative expenses were $4.2 million in Q3 2025, down from $5.2 million in Q3 2024, mainly due to reduced personnel-related costs [14] Pipeline Developments - Tebipenem HBr is being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and has shown non-inferiority to intravenous imipenem-cilastatin in the PIVOT-PO trial [3][7] - The PIVOT-PO trial results indicated an overall success rate of 58.5% for tebipenem HBr compared to 60.2% for imipenem-cilastatin, with a safety profile consistent with other carbapenem antibiotics [7] - The SPR720 program for nontuberculous mycobacterium pulmonary disease has been discontinued following a review of Phase 2a and Phase 1 trial data [4] Cash Position - As of September 30, 2025, Spero had cash and cash equivalents of $48.6 million, which is expected to fund operations into 2028 [14]

Core Viewpoint - Spero Therapeutics, Inc. is set to report its third quarter 2025 financial results and provide a business update on November 13, 2025, after market close, and will not host a conference call [1]. Company Overview - Spero Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with significant unmet medical needs [2].